We examined the effect of continuous intravenous infusion of epoprostenol (35 ng/kg/min) on severe portopulmonary hypertension caused by biliary atresia. Pulmonary hemodynamics improved and brain natriuretic peptide and human atrial natriureic peptide decreased to normal values during epoprostenol therapy. However, the improvement in pulmonary hemodynamics was not sufficient to permit liver transplantation. Our patient was obliged to stop epoprostenol therapy because of financial problems and epoprostenol was tapered off safely over 6 weeks.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kato, H., Katori, T., Nakamura, Y. et al. Moderate-Term Effect of Epoprostenol on Severe Portopulmonary Hypertension . Pediatr Cardiol 24, 50–53 (2003). https://doi.org/10.1007/s00246-002-0120-9
Issue Date:
DOI: https://doi.org/10.1007/s00246-002-0120-9